Biology Atlas

Map / The cascade

step · intermediate · partly written

Preclinical

One step of the screening cascade walk-through, from disease to clinic.

What is done

Laboratory-animal and in vitro studies of pharmacology, drug disposition and toxicology, on which the sponsor concludes it is reasonably safe to start human trials. The rule lists acute, subacute and chronic toxicity tests, tests of effects on reproduction and the developing fetus, special tests tied to the route of use, and in vitro toxicity studies; the kind, duration and scope vary with the proposed trials. Kept thin on purpose: queue item 6 (regulatory proof) will deepen it. 1

Established

Proves

That the sponsor, and the named individuals who evaluated the results, concluded it is reasonably safe to begin the proposed investigations. That is a judgement filed with the regulator, not proof of safety. 1

Established

Cannot prove

Safety in humans where the animal model lacks the human target or cell type. The 2006 TGN1412 first-in-human study is the documented case (see the modality note). 23

Reported, not yet replicated

Assays

Regulators require

An IND must contain adequate pharmacology and toxicology information from laboratory animals or in vitro, with the identity and qualifications of those who evaluated it and where the records are held; FDA guidance documents describe ways to meet this. Amendments follow as development proceeds. 1

Established

Reports

Modality notes

Animal safety tests fail silently when the species lacks the human target

Before the 2006 TGN1412 first-in-human study, safety testing in the species used for preclinical work gave no warning; all six healthy volunteers had a systemic inflammatory response. A later study judged the failure almost certainly explained by CD28 being absent from CD4 effector memory T cells in that species. The same logic applies to any modality whose action depends on a human-specific receptor, sequence or cell type. 23

See: Therapeutic monoclonal antibodies, TGN1412 (anti-CD28 superagonist antibody)

Reported, not yet replicated

Still open here

Not yet written: Costs, ML role, Scenarios.

Linked from

Sources

  1. US Food and Drug Administration. IND content and format (21 CFR 312.23). Electronic Code of Federal Regulations, Title 21, Part 312 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  2. Suntharalingam G, et al.. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028 (2006). paper; opened 2026-11-17 all records citing this
  3. Eastwood D, Findlay L, Poole S, et al.. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512-526 (2010). paper; opened 2026-11-17 all records citing this
History of this record (7)

This record has been changed 7 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Order
11
Stage
preclinical
Status
partly written
Last updated
2026-11-17
Record
content/cascade/preclinical.json